Physician profile
Ronald Roth
NPI 1891870234
$6,771.87
in general payments reported to CMS, 2019-2025
28 companies · $623 in 2025
The $623 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $828 · 2020: $774 · 2021: $763 · 2022: $1,185 · 2023: $1,552 · 2024: $1,048 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,222.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,459.82 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $985.57 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $513.53 | 2020-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $475.03 | 2020-2024 | Jardiance, Mounjaro |
| Janssen Pharmaceuticals, INC | $466.22 | 2019-2023 | Xarelto |
| Inspire Medical Systems, INC. | $332.65 | 2022-2025 | Inspire |
| Novo Nordisk INC | $328.76 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $292.48 | 2023-2025 | Evenity, Repatha, Otezla |
| Regeneron Healthcare Solutions, INC. | $248.86 | 2025 | Dupixent |
| Amarin Pharma, INC. | $198.91 | 2019-2021 | |
| Medtronic Vascular, INC. | $183.00 | 2020 | |
| Merck Sharp & Dohme LLC | $183.00 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Exact Sciences Corporation | $152.45 | 2023-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $137.70 | 2023 | |
| Pfizer INC. | $127.97 | 2020-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2024 | |
| Indivior INC. | $108.12 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $98.53 | 2019 | |
| Abbvie INC. | $81.69 | 2021-2024 | Vraylar |
| Boston Scientific Corporation | $67.20 | 2022-2023 | |
| Avvisto Therapeutics, LLC | $38.21 | 2024 | Cycloset |
| Daiichi Sankyo INC. | $37.88 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.21 | 2020-2021 | |
| Biogen, INC. | $23.76 | 2024 | Skyclarys |
| Tanabe Pharma America, INC. | $23.39 | 2023 | |
| Medicomp INC | $18.25 | 2025 | Telepatch Cardiac Monitor |
| Phadia US INC. | $16.27 | 2023 | Immunocap |
| Althera Pharmaceuticals LLC | $14.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.